Senescent cells: a therapeutic target in cardiovascular diseases

M Suda, KH Paul, T Minamino, JD Miller, A Lerman… - Cells, 2023 - mdpi.com
Senescent cell accumulation has been observed in age-associated diseases including
cardiovascular diseases. Senescent cells lack proliferative capacity and secrete senescence …

Therapeutic applications of mesenchymal stromal cells: paracrine effects and potential improvements

J Doorn, G Moll, K Le Blanc… - … Engineering Part B …, 2012 - liebertpub.com
Among the various types of cell-to-cell signaling, paracrine signaling comprises those
signals that are transmitted over short distances between different cell types. In the human …

Fibroblast growth factor regulation of neovascularization

M Murakami, M Simons - Current opinion in hematology, 2008 - journals.lww.com
Although fibroblast growth factors are potent angiogenic factors, they may indirectly control
neovascularization in concert with other growth factors. Thus, the unique role played by …

Cell therapy of peripheral arterial disease: from experimental findings to clinical trials

Z Raval, DW Losordo - Circulation research, 2013 - Am Heart Assoc
The age-adjusted prevalence of peripheral arterial disease in the US population was
estimated to approach 12% in 1985, and as the population ages, the overall population …

Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in …

S Matoba, T Tatsumi, T Murohara, T Imaizumi… - American heart …, 2008 - Elsevier
BACKGROUND: Angiogenic cell therapy by intramuscular injection of autologous bone
marrow mononuclear cells was first attempted in patients with peripheral artery disease …

Endothelial progenitor cells: novel biomarker and promising cell therapy for cardiovascular disease

S Sen, SP McDonald, PTH Coates… - Clinical science, 2011 - portlandpress.com
Bone-marrow-derived EPCs (endothelial progenitor cells) play an integral role in the
regulation and protection of the endothelium, as well as new vessel formation. Peripheral …

Intramuscular Transplantation of G-CSF-Mobilized CD34+ Cells in Patients With Critical Limb Ischemia: A Phase I/IIa, Multicenter, Single-Blinded, Dose-Escalation …

A Kawamoto, M Katayama, N Handa, M Kinoshita… - Stem …, 2009 - academic.oup.com
A number of preclinical studies have indicated the therapeutic potential of endothelial
progenitor cells for vascular regeneration in ischemic diseases. A phase I/IIa clinical trial of …

Heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: a noninvasive therapeutic regimen

A Shabbir, D Zisa, G Suzuki… - American Journal of …, 2009 - journals.physiology.org
Heart failure carries a poor prognosis with few treatment options. While myocardial stem cell
therapeutic trials have traditionally relied on intracoronary infusion or intramyocardial …

[HTML][HTML] Therapeutic angiogenesis-based strategy for peripheral artery disease

J Han, L Luo, O Marcelina, V Kasim, S Wu - Theranostics, 2022 - ncbi.nlm.nih.gov
Peripheral artery disease (PAD) poses a great challenge to society, with a growing
prevalence in the upcoming years. Patients in the severe stages of PAD are prone to …

Role of host tissues for sustained humoral effects after endothelial progenitor cell transplantation into the ischemic heart

HJ Cho, N Lee, JY Lee, YJ Choi, M Ii… - The Journal of …, 2007 - rupress.org
Noncellular differentiation effects have emerged as important mechanisms mediating
therapeutic effects of stem or progenitor cell transplantation. Here, we investigated the …